GlassScriptPhysician profile
Ernesto C Guerra
NPI 1558366435
$11,143.00
in general payments reported to CMS, 2019-2025
38 companies · $1,682 in 2025
The $1,682 reported for 2025 was more than what 75% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,028 · 2020: $1,254 · 2021: $1,661 · 2022: $1,483 · 2023: $1,494 · 2024: $1,542 · 2025: $1,682.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,717.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,717.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,542.78 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,489.81 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $1,245.97 | 2020-2025 | Tremfya, Stelara, Simponi Aria |
| Olympus America INC. | $813.19 | 2020-2025 | Visiglide, Endoclot Phs, Single Use Electrosurgical Knife Kd-655 |
| Gilead Sciences, INC. | $715.33 | 2019-2025 | Livdelzi |
| Allergan, INC. | $380.11 | 2019-2020 | |
| Pfizer INC. | $352.86 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $338.09 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Shionogi INC | $241.43 | 2019 | |
| Ironwood Pharmaceuticals, INC | $188.34 | 2019-2024 | Linzess |
| Lilly USA, LLC | $168.30 | 2024-2025 | Omvoh |
| Intercept Pharmaceuticals, INC. | $159.67 | 2019-2022 | |
| Ucb, INC. | $113.41 | 2019-2020 | |
| Echosens North America, INC. | $107.90 | 2025 | Fibroscan |
| Nestle Healthcare Nutrition INC. | $106.59 | 2021-2023 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $103.40 | 2019-2023 | Suflave, Sutab |
| Evoke Pharma, INC. | $93.63 | 2020-2021 | |
| Redhill Biopharma INC. | $87.79 | 2020-2023 | Talicia |
| Qol Medical, LLC | $87.73 | 2021-2025 | Sucraid, Sucraid |
| Smith+Nephew, INC. | $81.34 | 2022 | |
| Celgene Corporation | $78.64 | 2021-2023 | Zeposia |
| Micro-Tech Endoscopy USA, INC. | $71.71 | 2020-2022 | |
| Phathom Pharmaceuticals, INC. | $70.24 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $67.18 | 2025 | Ibsrela |
| Aimmune Therapeutics, INC. | $65.08 | 2024-2025 | Zenpep |
| Merck Sharp & Dohme LLC | $52.49 | 2019-2023 | Dificid |
| Ipsen Biopharmaceuticals, INC | $45.00 | 2024-2025 | Iqirvo |
| Romark Laboratories, Lc | $41.24 | 2020 | |
| Vivus LLC | $36.89 | 2022-2025 | Pancreaze |
| Alfasigma USA, INC. | $36.21 | 2020 | |
| Mauna Kea Technologies, INC. | $33.48 | 2020 | |
| Ferring Pharmaceuticals INC. | $30.30 | 2023 | Rebyota |
| Janssen Pharmaceuticals, INC | $29.67 | 2022 | |
| Novo Nordisk INC | $20.18 | 2025 | Wegovy |
| Azurity Pharmaceuticals, INC. | $16.13 | 2025 | Suflave |
| Madrigal Pharmaceuticals | $15.91 | 2025 | Rezdiffra |
| Alexion Pharmaceuticals, INC. | $14.98 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$28,506.37 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ernesto Guerra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.